1260590-28-0Relevant articles and documents
PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION
-
Paragraph 0240; 0244; 0245; 0246, (2018/12/13)
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a, and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.
